Adults 39 to 49, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
ReactancePrimary· 24 hours
In response to mammography evidence, feeling that the information is manipulative or biased. 4 questions total, each on a 7 point Likert scale, with mean scores that range from 1 to 5. Higher mean scores reflect greater reactance.
Response to screening benefits
Group
Value
95% CI
Women Age 39-49 in the United States
2.28
± 0.71
Response to false positives
Group
Value
95% CI
Women Age 39-49 in the United States
2.45
± 0.75
Response to overdiagnosis
Group
Value
95% CI
Women Age 39-49 in the United States
2.55
± 0.80
DisbeliefPrimary· 24 hours
In response to mammography evidence, feeling that the evidence is not accurate or believable. 4 questions total, each on a 5 point Likert scale, with mean scores that range from 1 to 5. Higher mean score reflects more disbelief in the information.
Response to screening benefits
Group
Value
95% CI
Women Age 39-49 in the United States
2.06
± 0.61
Response to false positives
Group
Value
95% CI
Women Age 39-49 in the United States
2.32
± 0.63
Response to overdiagnosis
Group
Value
95% CI
Women Age 39-49 in the United States
2.41
± 0.68
Source DerogationPrimary· 24 hours
In response to mammography evidence, feeling that the source of the evidence is not trustworthy or competent. 4 questions total, each on a 5 point Likert scale, with mean scores that range from 1 to 5. Higher mean score reflects more source derogation.
Group
Value
95% CI
Women Age 39-49 in the United States
2.56
± 0.09
Self ExemptionPrimary· 24 hours
Feeling that mammography evidence is not relevant to oneself.34 questions total, each on a 5 point Likert scale, with mean scores that range from 1 to 5. Higher mean scores indicate greater belief that the information is not self relevant.
Response to screening benefits
Group
Value
95% CI
Women Age 39-49 in the United States
2.20
± 0.70
Response to false positives
Group
Value
95% CI
Women Age 39-49 in the United States
2.21
± 0.71
Response to overdiagnosis
Group
Value
95% CI
Women Age 39-49 in the United States
2.32
± 0.72
Screening IntentionsPrimary· 24 hours
Intentions to engage in mammography screening. Options will include: 1. I am planning to start/continue having regular mammograms this year. 2. I am planning to wait until I'm older but before age 50 to have my first/next mammogram. 3. I am planning to wait until I am 50 to have my first/next mammogram. 4. I am not planning to have a mammogram in the future at any age
Have regular mammograms at current age
Group
Value
95% CI
Women Age 39-49 in the United States
286
Wait until older but before age 50
Group
Value
95% CI
Women Age 39-49 in the United States
100
Wait until age 50
Group
Value
95% CI
Women Age 39-49 in the United States
88
never have a mammogram
Group
Value
95% CI
Women Age 39-49 in the United States
21
Medical Mistrust Scale (Eaton et al., 2015)Secondary· 24 hours
6 question scale that assesses mistrust in healthcare providers. Calculated as mean trust (range 1-low trust to 5-high trust). Assessed both pre and post receipt of screening decision aid to evaluate change
Pre-DA trust
Group
Value
95% CI
Women Age 39-49 in the United States
3.11
± 0.69
Post-DA trust
Group
Value
95% CI
Women Age 39-49 in the United States
3.02
± 0.65
Sponsor's own description
Identify the prevalence and predictors of reactance, self-exemption, disbelief, source derogation in reaction to evidence about mammography benefits and harms, and consequences for decision-making and trust.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06920927 — Feasibility and Pilot Testing of "My Heart and CKD" Online Shared Decision Aid
· NA
· not yet recruiting
NCT06247371 — Impact of a Novel Heart Failure Medication Decision Aid
· NA
· completed
NCT06382194 — Decision Making Tool for Firearm Storage
· NA
· completed
NCT06189807 — Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
· NA
· active not recruiting
NCT05182008 — A Patient Decision Aid for Method of Early Abortion: a Randomized Control Trial
· NA
· completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
· Phase 2
· recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
· Phase 2
· recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer
· NA
· recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
· Phase 2
· recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
· not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
· Phase 3
· not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.
· NA
· not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
· EARLY_PHASE1
· not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes
· Phase 2
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 27 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05376241.